Navigation Links
Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
Date:6/13/2010

NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally. Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate.  In addition, no serious adverse safety events were reported for Octreolin.

The Company also announced that it was advancing towards its goal of beginning a pivotal trial by the end of the year for Octreolin in acromegaly, a hormonal disorder that results from an excess of growth hormone (GH).

Chiasma has submitted an Orphan Drug application to the US FDA for acromegaly and will submit an application for Orphan Medicinal Product Designation to the European Agency for the Evaluation of Medicinal Products (EMEA) shortly. The Company intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMEA equivalent, the Hybrid Application, in Europe.

Information on the Octreolin Trial

The Phase I trial was conducted in 12 healthy volunteers with a cross-over design in which subjects were each administered three single oral doses of Octreolin and a single subcutaneous injection of octreotide acetate as the reference drug (Sandostatin®). The primary objectives of the trial were to evaluate the safety, tolerability and PK of the three oral doses of Octreolin in comparison to the subcutaneous injection of octreotide acetate. Key findings included:


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... Genzyme Products, CAMBRIDGE, Mass., Sept. 18 Genzyme ... significant expansion of its,flagship manufacturing facility at Allston Landing ... space for manufacturing support,functions, and will allow for the ... by a ceremony featuring Massachusetts Governor,Deval L. Patrick, Boston ...
... - the New ISI Web of Knowledge - to ... Throughout the Country, PHILADELPHIA and LONDON, Sept. 18 ... TOC ; TSX: TOC) and,leading provider of information solutions ... Spain,s La Fundacion Espanola,para la Ciencia y la Tecnologia ...
... GSK Increases Research Effort to Target Drug-Resistant Gram Negative ... ... GlaxoSmithKline (NYSE:,GSK) today announced that it has signed an agreement ... Defense (DOD), to,identify and develop a new class of antibacterials targeting ...
Cached Biology Technology:Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 2GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 3
(Date:8/28/2014)... (ESA) is pleased to announce the selection of Dr. ... Honorary Membership acknowledges those who have served ESA for ... affairs of the Society that has reached an extraordinary ... ESA Governing Board and then voted on by the ... Awards Ceremony at Entomology 2014, ESA,s Annual Meeting in ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... Miami Beach, FL (March 5, 2010) Research presented ... Annual Meeting of the American Academy of Dermatology (Miami ... multiple perspectives, offering insights into how ingredient formulations, care ... are on display, discussing a wide range of topics, ...
... Genetics Society of America is pleased to announce the ... 1, 2010, at the University of British Columbia (UBC) ... investigators studying various aspects of eukaryotic biology in yeast. ... and a Canadian astronaut who is also a Member ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
Cached Biology News:P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 42010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: